Xtant Medical Holdings reported ineffective disclosure controls due to an inventory valuation material weakness as of September 30, 2026. It lost $16.1 million and used $10.3 million in operating activities during nine months, required covenant amendments, and withdrew 2026 guidance.
XTNT · Xtant Medical Holdings, Inc. · Documents
$0.26
-0.01 (-4.20%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$38.12M
Shares
140.29M
Volume · Nov 13
181.75K
Avg daily vol (3M)
1.67M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Nov 16
Quarterly report
10-Q
Ended Sep 30
Material weakness persists amid debt covenant pressure
Revenue $24.29M
▼ 27.0%
Net loss $3.56M
Diluted EPS -$0.03
Nov 16
Current report
8-K
Strategic review follows second consecutive quarterly guidance miss
Xtant Medical launched a board-led strategic review after missing guidance for a second consecutive quarter. Third-quarter revenue was $24.3 million, net loss was $3.6 million, adjusted EBITDA was a loss of $1.5 million, and previously issued full-year 2026 guidance will not be achieved.
Aug 11
Aug 11
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Revenue $23.03M
▼ 35.0%
Net loss $9.41M
Diluted EPS -$0.07
Aug 11
Aug 7
Jun 23
Jun 23
Jun 23
May 13
May 13
May 13
Quarterly report
10-Q
FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1
AI summary on its way
Revenue $20.88M
▼ 36.5%
Net loss $3.09M
Diluted EPS -$0.02
Apr 13
Mar 31
Mar 31
Mar 31
Annual report
10-K
FY2025, ended Dec 31
Annual report for FY2025
AI summary on its way
Revenue $133.93M
▲ 14.2%
Net income $4.97M
Diluted EPS $0.03
Mar 2
Jan 16
2025
Dec 3
Current report
8-K
Events of Dec 1
Completed an acquisition or sale of assets, Debt obligation accelerated or increased, Regulation FD disclosure
Nov 11
Earnings call
Q3 2025 earnings call
Nov 10
Current report
8-K
Events of Nov 7
Director or officer change, or executive pay, Shareholder vote results
Nov 10
Current report
8-K
Financial results
Nov 10
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $33.26M
▲ 19.0%
Net income $1.31M
Diluted EPS $0.01
Sep 15
Proxy statement
DEF 14A
Proxy statement
Sep 15
Annual report to holders
ARS
Annual report to holders
Sep 15
Proxy statement
DEFA14A
Proxy statement
Aug 12
Earnings call
Q2 2025 earnings call
Aug 12
Current report
8-K
Financial results, Regulation FD disclosure
Aug 12
Quarterly report
10-Q
FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $35.41M
▲ 18.3%
Net income $3.55M
Diluted EPS $0.02
Aug 8
Current report
8-K
Other events
Aug 4
Current report
8-K
Events of Aug 1
Director or officer change, or executive pay
Jul 8
Current report
8-K
Events of Jul 7
Entered into a material agreement, Regulation FD disclosure, Other events
May 12
Earnings call
Q1 2025 earnings call
May 12
Current report
8-K
Financial results
May 12
Quarterly report
10-Q
FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $32.9M
▲ 18.0%
Net income $58K
Diluted EPS $0.00
May 12
Registration statement
S-1
Registration statement
Apr 16
Current report
8-K
Events of Apr 15
Ended a material agreement, Financial results, Change in control, Regulation FD disclosure, Other events
Apr 11
Current report
8-K
Events of Apr 10
Entered into a material agreement
Mar 6
Earnings call
Q4 2024 earnings call
Mar 6
Current report
8-K
Financial results
Mar 6
Annual report
10-K
FY2024, ended Dec 31
Annual report for FY2024
Revenue $117.27M
▲ 28.4%
Net loss $16.45M
Diluted EPS -$0.12
2024
Nov 12
Earnings call
Q3 2024 earnings call
Nov 12
Current report
8-K
Financial results
Nov 12
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $27.94M
▲ 11.7%
Net loss $5.02M
Diluted EPS -$0.04
Sep 3
Current report
8-K
Other events
Sep 3
Registration statement
S-3
Registration statement
Aug 8
Current report
8-K
Financial results
Aug 8
Current report
8-K
Events of Aug 7
Entered into a material agreement, Unregistered sale of equity, Other events
Aug 8
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $29.94M
▲ 48.0%
Net loss $3.86M
Diluted EPS -$0.03
Jul 24
Current report
8-K
Events of Jul 23
Shareholder vote results
Showing 1–50 of 153 documents
Key facts
CIK
1453593
CUSIP
98420P308
13F (30d)
29 filings
23 filers
Visit website
Investor relations